Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial

BACKGROUND AND OBJECTIVE: Chronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT. METHODS: Patients were randomized to once‐daily fluticasone furoate/umeclidinium/vilanterol (FF/...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Philip J., Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Lipson, David A., Maghzal, Ghassan J., Martinez, Fernando J., Midwinter, Dawn, Singh, Dave, Tombs, Lee, Wise, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804213/
https://www.ncbi.nlm.nih.gov/pubmed/35970518
http://dx.doi.org/10.1111/resp.14339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804213/
https://www.ncbi.nlm.nih.gov/pubmed/35970518
http://dx.doi.org/10.1111/resp.14339

Ejemplares similares